Xvivo Perfusion AB (publ) (LON:0RKL)
London
· Delayed Price · Currency is GBP · Price in SEK 459.50
-3.84 (-0.83%)
At close: Feb 21, 2025
Xvivo Perfusion AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 822.42 | 597.54 | 415.29 | 258.39 | 179.86 | Upgrade
|
| Revenue Growth (YoY) | 37.63% | 43.88% | 60.73% | 43.66% | -18.55% | Upgrade
|
| Cost of Revenue | 206 | 152.43 | 118.34 | 70.11 | 50.13 | Upgrade
|
| Gross Profit | 616.42 | 445.11 | 296.96 | 188.28 | 129.73 | Upgrade
|
| Selling, General & Admin | 379.77 | 309.21 | 223.38 | 153.38 | 107.71 | Upgrade
|
| Research & Development | 148.33 | 135.94 | 69.34 | 54.04 | 66.74 | Upgrade
|
| Other Operating Expenses | -0.04 | -5.43 | -0.22 | -0.39 | -0.53 | Upgrade
|
| Operating Expenses | 528.06 | 439.72 | 292.5 | 207.02 | 173.92 | Upgrade
|
| Operating Income | 88.35 | 5.4 | 4.45 | -18.74 | -44.19 | Upgrade
|
| Interest Expense | - | -1.19 | -0.61 | -0.28 | -0.36 | Upgrade
|
| Interest & Investment Income | 111.6 | 8.85 | 2.12 | - | 0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 9.69 | 17.09 | 5.98 | -12.6 | Upgrade
|
| Other Non Operating Income (Expenses) | - | 3.75 | -0.49 | 19.75 | -0.2 | Upgrade
|
| EBT Excluding Unusual Items | 199.95 | 26.49 | 22.58 | 6.71 | -57.26 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -1 | -0.26 | -0.04 | - | Upgrade
|
| Other Unusual Items | - | 69.04 | - | - | - | Upgrade
|
| Pretax Income | 199.95 | 94.52 | 22.31 | 6.67 | -57.26 | Upgrade
|
| Income Tax Expense | 27.77 | 2.7 | 3.89 | -1.49 | -13.53 | Upgrade
|
| Net Income | 172.18 | 91.82 | 18.43 | 8.15 | -43.74 | Upgrade
|
| Net Income to Common | 172.18 | 91.82 | 18.43 | 8.15 | -43.74 | Upgrade
|
| Net Income Growth | 87.52% | 398.29% | 126.04% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 31 | 30 | 30 | 29 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 32 | 30 | 30 | 29 | 27 | Upgrade
|
| Shares Change (YoY) | 5.73% | 1.39% | 2.04% | 6.49% | 1.39% | Upgrade
|
| EPS (Basic) | 5.47 | 3.07 | 0.62 | 0.28 | -1.61 | Upgrade
|
| EPS (Diluted) | 5.44 | 3.07 | 0.62 | 0.28 | -1.61 | Upgrade
|
| EPS Growth | 77.35% | 394.73% | 121.43% | - | - | Upgrade
|
| Free Cash Flow | 40.59 | 3.27 | 9.67 | -22.25 | -14.9 | Upgrade
|
| Free Cash Flow Per Share | 1.28 | 0.11 | 0.33 | -0.77 | -0.55 | Upgrade
|
| Gross Margin | 74.95% | 74.49% | 71.51% | 72.87% | 72.13% | Upgrade
|
| Operating Margin | 10.74% | 0.90% | 1.07% | -7.25% | -24.57% | Upgrade
|
| Profit Margin | 20.94% | 15.37% | 4.44% | 3.15% | -24.32% | Upgrade
|
| Free Cash Flow Margin | 4.94% | 0.55% | 2.33% | -8.61% | -8.28% | Upgrade
|
| EBITDA | 149.57 | 19.03 | 13.3 | -11.7 | -36.61 | Upgrade
|
| EBITDA Margin | 18.19% | 3.19% | 3.20% | -4.53% | -20.35% | Upgrade
|
| D&A For EBITDA | 61.22 | 13.64 | 8.85 | 7.04 | 7.58 | Upgrade
|
| EBIT | 88.35 | 5.4 | 4.45 | -18.74 | -44.19 | Upgrade
|
| EBIT Margin | 10.74% | 0.90% | 1.07% | -7.25% | -24.57% | Upgrade
|
| Effective Tax Rate | 13.89% | 2.86% | 17.42% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.